Should I Buy EVO? EVO 2026 Analysis

Should You Buy Evotec SE (EVO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.530

1 Day change

0.28%

52 Week Range

4.800

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient investor: the setup lacks a clear momentum trigger and Intellectia signals are absent.
Price is hovering just above the pivot/support area (3.622) after a -1.98% regular-session drop and additional weakness post-market (3.715), which tilts risk to a near-term pullback.
Fundamental picture from the latest quarter remains weak (revenue down YoY and profitability still negative), so there isn’t a strong “fundamental floor” to confidently buy aggressively here.
Wall Street upside targets are high (EUR 10), but current tape/financial trend does not confirm an immediate entry; this is more of a watchlist/hold than a buy-now.

Technical Analysis

Trend/Momentum: MACD histogram is below zero (-0.00661) and still bearish, though negatively contracting (bearish momentum is easing rather than reversing).
RSI (6): 56.14 (neutral), consistent with a choppy/indecisive tape rather than a strong uptrend.
Moving averages: converging, suggesting consolidation and lack of a clean directional trend.
Key levels: Pivot 3.622 (near current), support S1 3.454 then S2 3.35; resistance R1 3.79 then R2 3.894. A clean break and hold above ~3.79–3.89 would improve the buy case; losing 3.622 increases downside odds toward 3.454.
Pattern-based forecast (similar candlesticks): points to mild downside over the next month (-1.2%), not supportive of an immediate buy.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Positive Catalysts

- Analyst support remains constructive: Berenberg initiated with a Buy and EUR 10 target (2026-02-03); RBC maintains Outperform (though target reduced previously).
- If price holds above the 3.622 pivot and reclaims 3.79–3.89, technical confirmation could attract short-term buyers.

Neutral/Negative Catalysts

- No clear event-driven catalysts in the provided news flow for Evotec (the listed news items appear unrelated), reducing the odds of an immediate sentiment-driven pop.
- Near-term price action is weak (down regular session and post-market), and MACD remains below zero.
- Statistical/pattern outlook suggests mild downside over the next month (-1.2%).

Financial Performance

Latest quarter provided: 2025/Q3.
Revenue: 191,553,770.13 (-5.70% YoY), indicating contraction rather than growth.
Net income: -50,360,780.86 (15.65% YoY improvement but still a loss).
EPS: -0.28 (12.00% YoY improvement but still negative).
Gross margin: -0.04 (down -100.40% YoY), a major red flag for operating quality in the period shown.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent rating/target trend: generally supportive but with some trimming—RBC lowered PT to EUR 10 from EUR 11.20 (2025-11-12) while keeping Outperform; Berenberg initiated Buy with EUR 10 PT (2026-02-03).
Wall Street pros (bull case): platform/positioning in drug discovery (incl. iPSC-based work) and manufacturing trends cited by Berenberg; targets imply substantial upside from current price.
Wall Street cons (bear case): targets have been reduced vs prior levels and the company’s latest reported quarter shows shrinking revenue and ongoing losses, which can cap near-term enthusiasm.
Influential/political trading: No recent congress trading data available; hedge fund and insider trend signals are Neutral with no significant recent activity noted.

3 Analyst Rating

Wall Street analysts forecast EVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVO is 6 USD with a low forecast of 5 USD and a high forecast of 7 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

1 Sell

Moderate Buy

Current: 3.520

Low

Averages

High

Current: 3.520

Low

Averages

High

Berenberg

NULL

Buy

initiated

€10

AI Analysis

2026-02-03

Reason

Berenberg

Price Target

€10

AI Analysis

2026-02-03

initiated

NULL

Buy

Reason

Berenberg initiated coverage of Evotec with a Buy rating and EUR 10 price target. The firm says the company benefits from a "leading position in important fields" such as drug discovery based on induced pluripotent stem cells, as well as the shift to continuous manufacturing and favorable underlying market trends.

Berenberg

Hold

downgrade

$630 -> $620

2026-01-20

Reason

Berenberg

Price Target

$630 -> $620

2026-01-20

downgrade

Hold

Reason

Berenberg lowered the firm's price target on Evolution AB to SEK 620 from SEK 630 and keeps a Hold rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EVO

Unlock Now

EVO Should I Buy

EVO Should I Buy

Should You Buy Evotec SE (EVO) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch